Printer Friendly

Active Surveillance is 30% Higher in Men Receiving Genomic Prostate Score Test.

M2 PHARMA-February 8, 2018-Active Surveillance is 30% Higher in Men Receiving Genomic Prostate Score Test

(C)2018 M2 COMMUNICATIONS

- Geneva, Switzerland- and Redwood City, California-based genomic-based diagnostic test provider, Genomic Health Inc. (NASDAQ: GHDX) has published real-world clinical evidence demonstrating that use of the Oncotype DX Genomic Prostate Score (GPS) test resulted in significantly higher use of active surveillance at six and 12 months compared to no testing within the same time period, the company said.

Results of this large, independently conducted study, published in Reviews in Urology, bring the collective published clinical utility evidence to four studies in nearly 8,300 men, demonstrating the actionable impact of the GPS test in treatment planning.

Using the Optum research database of electronic health records and administrative claims from a large US health insurer offering both commercial and Medicare Advantage health plans, the study reviewed nearly 10,000 de-identified patient records to assess active surveillance use for patients tested with the Oncotype DX GPS test.

Results showed that active surveillance use was more than 30% higher in men who received the GPS test than in men who did not receive the genomic test.

The Oncotype DX Genomic Prostate Score test analyzes 17 genes across four biological pathways from tumor tissue removed during biopsy to provide an individual score that, in combination with other clinical factors, further clarifies the current and future risk of the cancer prior to treatment intervention.

The test enables confident treatment decisions to provide the opportunity for low- and intermediate-risk patients to avoid prostatectomy or radiation and their side effects while identifying men who need immediate definitive treatment.

Genomic Health is a provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease. Its Oncotype IQ portfolio of genomic tests and services currently consists of the flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 800,000 cancer patients worldwide.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 8, 2018
Words:338
Previous Article:Eisai Publishes Results of Subgroup Analysis of Eribulin Mesylate in Previously Treated Patients with Advanced Liposarcoma.
Next Article:Novartis receives FDA approval to update Cosentyx label.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters